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Gilteritinib or Chemotherapy for Relapsed
or Refractory FLT3-Mutated AML
A.E. Perl, G. Martinelli, J.E. Cortes, A. Neubauer, E. Berman, S. Paolini,
P. Montesinos, M.R. Baer, R.A. Larson, C. Ustun, F. Fabbiano, H.P. Erba,
A. Di Stasi, R. Stuart, R. Olin, M. Kasner, F. Ciceri, W.-C. Chou, N. Podoltsev,
C. Recher, H. Yokoyama, N. Hosono, S.-S. Yoon, J.-H. Lee, T. Pardee, A.T. Fathi,
C. Liu, N. Hasabou, X. Liu, E. Bahceci, and M.J. Levis
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BACKGROUND
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Copyright © 2019 Massachusetts Medical Society.

Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations
in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage chemotherapy. Gilteritinib is an oral, potent, selective FLT3 inhibitor with
single-agent activity in relapsed or refractory FLT3-mutated AML.
METHODS

In a phase 3 trial, we randomly assigned adults with relapsed or refractory FLT3mutated AML in a 2:1 ratio to receive either gilteritinib (at a dose of 120 mg per
day) or salvage chemotherapy. The two primary end points were overall survival
and the percentage of patients who had complete remission with full or partial
hematologic recovery. Secondary end points included event-free survival (freedom
from treatment failure [i.e., relapse or lack of remission] or death) and the percentage of patients who had complete remission.
RESULTS

Of 371 eligible patients, 247 were randomly assigned to the gilteritinib group
and 124 to the salvage chemotherapy group. The median overall survival in the
gilteritinib group was significantly longer than that in the chemotherapy group
(9.3 months vs. 5.6 months; hazard ratio for death, 0.64; 95% confidence interval
[CI], 0.49 to 0.83; P<0.001). The median event-free survival was 2.8 months in the
gilteritinib group and 0.7 months in the chemotherapy group (hazard ratio for
treatment failure or death, 0.79; 95% CI, 0.58 to 1.09). The percentage of patients
who had complete remission with full or partial hematologic recovery was 34.0%
in the gilteritinib group and 15.3% in the chemotherapy group (risk difference,
18.6 percentage points; 95% CI, 9.8 to 27.4); the percentages with complete remission were 21.1% and 10.5%, respectively (risk difference, 10.6 percentage points;
95% CI, 2.8 to 18.4). In an analysis that was adjusted for therapy duration, adverse
events of grade 3 or higher and serious adverse events occurred less frequently in
the gilteritinib group than in the chemotherapy group; the most common adverse
events of grade 3 or higher in the gilteritinib group were febrile neutropenia
(45.9%), anemia (40.7%), and thrombocytopenia (22.8%).
CONCLUSIONS

Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or
refractory FLT3-mutated AML. (Funded by Astellas Pharma; ADMIRAL ClinicalTrials
.gov number, NCT02421939.)
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P

atients with acute myeloid leukemia (AML) whose disease is refractory to,
or relapses after, induction chemotherapy
have a dismal prognosis with standard chemotherapy.1-4 FMS-like tyrosine kinase 3 (FLT3), a
cytokine receptor tyrosine kinase that is expressed in early hematopoietic stem and progenitor cells, regulates their proliferation and
differentiation.5 FLT3-activating mutations occur
in approximately 30% of patients with AML,6
primarily as in-frame internal tandem duplications (ITD) within the juxtamembrane region or
as missense point mutations in the tyrosine kinase domain (TKD).7-9 In patients with AML, the
presence of the FLT3 ITD mutation adversely affects survival, both at diagnosis and on failure
of the initial therapy.10-12
Several FLT3 tyrosine kinase inhibitors, either
under development or approved for the treatment of AML, vary in kinase selectivity, potency,
and clinical activity.13-17 Midostaurin, a multitargeted inhibitor, is approved in combination with
standard cytarabine and daunorubicin–based
chemotherapy for patients with newly diagnosed
FLT3-mutated AML.18,19 However, for patients with
relapsed or refractory AML, neither midostaurin
nor lestaurtinib has conferred durable clinical
benefit as a single agent.13,14,20 Sorafenib showed
clinical activity in patients with AML that was
positive for the FLT3 ITD mutation, but data
from randomized trials that support its use in
that context are scarce.16 The FLT3 inhibitor
quizartinib showed single-agent activity in patients with relapsed or refractory AML with the
FLT3 ITD mutation,21 but responses were shortlived, probably owing to FLT3 TKD mutations
that emerged during treatment.22 Similar resistance is seen with sorafenib.23 Furthermore,
quizartinib is myelosuppressive, probably owing
to its activity against other hematopoietic tyrosine kinases, such as c-Kit.24
Gilteritinib is a new, highly selective, oral FLT3
inhibitor with activity against both FLT3 mutation subtypes (ITD and TKD) and weak activity
against c-Kit.25,26 Gilteritinib also inhibits the
tyrosine kinase AXL, which is implicated in FLT3
inhibitor resistance.26,27 In a phase 1–2 study,
single-agent gilteritinib therapy resulted in sustained inhibition of FLT3 autophosphorylation
and, at doses of at least 80 mg per day, led to
41% of the patients with relapsed or refractory
FLT3-mutated AML having a composite complete
n engl j med 381;18

remission (complete remission with or without
normal hematologic recovery); a starting dose of
120 mg per day was recommended for further
study.28 To investigate the clinical benefit of
gilteritinib in the treatment of relapsed or refractory FLT3-mutated AML, we conducted a multicenter, randomized trial comparing gilteritinib
with conventional salvage chemotherapy regimens.

Me thods
Trial Design and Oversight

The randomized, phase 3 ADMIRAL trial was
conducted at 107 centers in 14 countries and was
sponsored by Astellas Pharma. The trial was reviewed and approved by the institutional review
board or ethics committee at each participating
center and was conducted in accordance with
the principles of the Declaration of Helsinki. All
the patients provided written informed consent
at enrollment.
Two authors who were employees of the
sponsor designed the trial in collaboration with
four academic authors. Investigators gathered
and analyzed the data and submitted case-report
forms to the sponsor, which performed data
monitoring and statistical analyses. All the authors
had access to the trial data and were involved in
data interpretation. The authors and the sponsor
vouch for the completeness and accuracy of the
data and for the fidelity of the trial to the protocol (available with the full text of this article at
NEJM.org). The first and last authors wrote the
manuscript, with additional writing and editorial
assistance provided by medical writers who were
funded by the sponsor.
Patients

Patients 18 years of age or older were eligible if
their disease was refractory to one or two cycles
of conventional anthracycline-containing induction therapy or if they had hematologic relapse
after a complete remission. Patients who were
not candidates for anthracycline-containing induction regimens could participate if they had
completed at least one cycle of alternative standard therapy that had been judged by the investigators as the appropriate choice to induce remission. At enrollment, patients’ bone marrow
and blood samples were screened for FLT3 mutations by a central laboratory. Enrollment on the
basis of local testing for the FLT3 mutation was
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transplantation continued in the trial and could
resume gilteritinib therapy 30 to 90 days after
the transplantation if they had engraftment without relapse and no uncontrolled complications
of transplantation.

FLT3 Mutations

Patients were required to have FLT3 ITD or TKD
D835 or I836 mutations. The central laboratory
(Invivoscribe) used a polymerase chain reaction–
based assay that was modeled on published methods (LeukoStrat CDx).29 FLT3 mutations were
considered to be present if the mutant-to-nonmutant allelic ratio was at least 0.05. The median
FLT3 ITD allelic ratio was established at 0.77, with
a high FLT3 ITD allelic ratio defined as 0.77 or
greater and a low ratio as less than 0.77.
Randomization and Treatments

Enrolled patients were randomly assigned in a
2:1 ratio by an interactive response technology
system to receive once-daily gilteritinib (120 mg)
or salvage chemotherapy. Randomization was
stratified according to response to previous therapy and the chosen chemotherapy, which was
selected by the local investigator before randomization from four possible options: mitoxantrone,
etoposide, and cytarabine (MEC)20; fludarabine,
cytarabine, granulocyte colony-stimulating factor,
and idarubicin (FLAG-IDA)30; low-dose cytarabine; and azacitidine. MEC and FLAG-IDA were
considered to be high-intensity regimens, and
low-dose cytarabine and azacitidine were considered to be low-intensity regimens.
Gilteritinib or chemotherapy was administered
in 28-day cycles. Patients receiving high-intensity
chemotherapy were assessed for response on or
after day 15 to determine the need for a second
induction cycle; response was measured on day 1
of cycle 2. Gilteritinib or low-intensity chemotherapy was administered until documentation
of a lack of clinical benefit or the occurrence of
toxic effects or other discontinuation criterion as
defined in the protocol. Responses to gilteritinib
or low-intensity chemotherapy were assessed on
day 1 of cycles 2 and 3 and every two to three
cycles thereafter. No crossover between treatment
groups was permitted. Patients in the gilteritinib
group who did not have a protocol-defined composite complete remission at the dose of 120 mg
per day could escalate the dose to 200 mg per
day; those who had a response and proceeded to

1730
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End Points and Assessments

The two primary end points were overall survival
and the percentage of patients who had complete
remission with full or partial hematologic recovery. Key secondary end points were event-free
survival (defined as freedom from treatment failure [i.e., relapse or lack of remission] or death)
and the percentage of patients with complete
remission. Complete remission with full or partial hematologic recovery was evaluated in an
interim analysis in the gilteritinib group only
and was summarized in the final analysis for
both treatment groups. Overall survival, eventfree survival, complete remission, and other end
points were evaluated in the final analysis. Best
response was noted at any postbaseline visit.
Treatment response was assessed with the
use of modified International Working Group
criteria (Table S1 in the Supplementary Appendix,
available at NEJM.org).31 Minimal residual disease was not assessed. Safety was assessed by
evaluating the incidence of adverse events, including evaluation of vital signs, and results from
clinical laboratory tests, electrocardiograms, and
ophthalmologic examinations. Patient-reported
outcomes (from the EuroQoL Group 5-Dimension
5-Level [EQ-5D-5L] instrument32 and the Functional Assessment of Cancer Therapy–Leukemia33
questionnaire) are not presented here. Nextgeneration sequencing for AML-associated mutations was performed in bone marrow or blood
DNA samples obtained at baseline (Table S2).
Expression of AXL (a receptor tyrosine kinase
associated with drug resistance) was analyzed by
means of flow cytometry. The postbaseline transfusion status (assessed 29 days after first dose
until the last treatment dose) was evaluated in
patients who received gilteritinib treatment for
at least 84 days; transfusion independence was
noted if no red-cell or platelet transfusions were
administered for 56 consecutive days during the
postbaseline period. (Additional information about
FLT3 mutations, treatments, dose modifications,
and assessments is provided in the protocol and
the Supplementary Appendix.)
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Statistical Analysis

Assuming a 2:1 randomization ratio and that
10% of the patients would discontinue the trial,
we calculated that a planned sample of 369 patients would provide the trial with approximately 90% power to detect a difference in the estimated median overall survival between the
gilteritinib group (7.7 months) and the salvage
chemotherapy group (5.0 months) (hazard ratio
for death, 0.65) on the basis of 258 deaths at a
one-sided alpha level of 0.0245. The first planned
interim analysis — to evaluate the primary end
point of the percentage of patients who had
complete remission with full or partial hematologic recovery — occurred when approximately
141 patients in the gilteritinib group reached the
time point of at least 112 days (four treatment
cycles) after the receipt of first dose or after
randomization; the interim evaluation of complete remission with full or partial hematologic
recovery rate had no effect on trial conduct. The
planned final analysis was performed when approximately 258 deaths had occurred.
Two-sided P values for the analysis of overall
survival were determined with the use of the
stratified log-rank test; the Kaplan–Meier method
and the Greenwood formula were used to determine overall survival and event-free survival. The
statistical analysis plan excluded provisions for
multiplicity correction in the evaluation of secondary and other outcomes. These results are
reported as point estimates and 95% confidence
intervals without adjustment for multiplicity and
should not be used to infer definitive treatment
effects. Final efficacy and safety analyses were
performed in the intention-to-treat population
(all patients who underwent randomization) and
the safety population (all patients who had received at least one dose of trial treatment), respectively. (Details regarding the statistical analysis
are provided in the Supplementary Appendix.)

R e sult s
Patients

From October 20, 2015, to February 20, 2018, a
total of 625 patients entered screening. The
event cutoff of 258 deaths, which triggered the
final analysis, occurred on September 17, 2018;
the database was locked on October 19, 2018. A
total of 371 eligible patients underwent randomi

n engl j med 381;18

zation; 247 were assigned to the gilteritinib group
and 124 to the chemotherapy group (Fig. 1 and
Table 1). Overall, 60.6% of the patients had relapsed AML (median duration of first remission,
6.0 months; range, 0.3 to 60.0), and 39.4% had
primary refractory disease. Most patients (83.8%)
had received previous induction therapy with
anthracyclines but not FLT3 inhibitors (87.6%);
21 patients (5.7%) had received the FLT3 inhibitor
midostaurin. Receipt of previous hematopoieticcell transplantation did not affect patient assignment to the high-intensity and low-intensity
chemotherapy regimens. Nearly all the patients
(94.1%) who received high-intensity chemotherapy
received one treatment cycle. The median duration of low-intensity chemotherapy was 4 weeks
(low-dose cytarabine, 4 weeks [range, 2 to 31];
azacitidine, 4 weeks [range, 1 to 26]). The median
number of cycles of gilteritinib therapy received
was 5 (range, 1 to 33).
At the time of this analysis, 110 patients
remained alive and 38 were continuing therapy
with gilteritinib. Common reasons for the discontinuation of gilteritinib were relapse, progression, or lack of efficacy (50.2%), death (14.6%),
and adverse events (11.3%). Common reasons for
the discontinuation of chemotherapy were relapse,
progression, or lack of efficacy (39.5%), withdrawal by the patient (8.1%), physician decision
(8.9%), and death (8.1%).
Efficacy

The median duration of follow-up for overall
survival was 17.8 months. The median overall
survival was significantly longer among patients
in the gilteritinib group than among those in the
chemotherapy group (9.3 months vs. 5.6 months;
two-sided P<0.001) (Fig. 2A). The hazard ratio
for death with gilteritinib as compared with
chemotherapy was 0.64 (95% confidence interval
[CI], 0.49 to 0.83). The percentages of patients
who were alive at 1 year were 37.1% in the gilteri
tinib group and 16.7% in the chemotherapy
group. A consistent pattern of longer survival
with gilteritinib than with chemotherapy was
noted across multiple subgroups, including the
high-intensity and low-intensity chemotherapy
cohorts (Fig. 2B) and the high FLT3 ITD allelic
ratio subgroup (median overall survival, 7.1 vs.
4.3 months; hazard ratio for death, 0.49; 95%
CI, 0.34 to 0.71). Among patients with primary
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625 Patients with relapsed or refractory AML were
screened for FLT3 mutations and trial eligibility

254 Were excluded

371 With relapsed or refractory FLT3-mutated
AML underwent randomization
(intention-to-treat population)

247 Were assigned to receive
gilteritinib, 120 mg/day

124 Were assigned to receive
salvage chemotherapy

1 Did not receive trial therapy

15 Did not receive trial therapy

246 Received gilteritinib and were
included in safety population

109 Received salvage chemotherapy and
were included in safety population
28 Received MEC
40 Received FLAG-IDA
16 Received low-dose cytarabine
25 Received azacitidine

63 Underwent hematopoietic stem-cell
transplantation

19 Underwent hematopoietic stem-cell
transplantation
109 Discontinued trial
49 Had lack of efficacy,
progressive disease,
or relapse
19 Completed treatment
11 Were withdrawn by
physician
10 Withdrew
10 Died
5 Had adverse event
4 Had other reason
1 Had protocol deviation

208 Discontinued trial
124 Had lack of efficacy,
progressive disease,
or relapse
36 Died
28 Had adverse event
11 Were withdrawn by
physician
5 Withdrew
4 Had other reason

38 Are continuing in the trial

0 Are continuing in the trial

Figure 1. Screening, Randomization, and Treatment.
Of the 625 patients screened, 254 did not undergo randomization: 236 of 625 patients (37.8%) did not continue
to randomization because inclusion or exclusion criteria were not met or because of absence of a mutation in the
FMS-like tyrosine kinase 3 gene (FLT3), 10 patients (1.6%) had an adverse event, and 8 (1.3%) withdrew from the
trial. A total of 25 of 63 patients in the gilteritinib group and all 19 patients in the salvage chemotherapy group who
underwent hematopoietic stem-cell transplantation subsequently discontinued treatment. The safety population
comprised all the patients who had received at least one dose of trial treatment. AML denotes acute myeloid leukemia;
FLAG-IDA fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin; and MEC mitoxantrone,
etoposide, and cytarabine.
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Table 1. Demographic and Clinical Characteristics of the Patients at Baseline (Intention-to-Treat Population).*
Characteristic

All Patients
(N = 371)

Gilteritinib
(N = 247)

Salvage Chemotherapy
(N = 124)

62.0

62.0

61.5

Age — yr
Median
Range

19.0–85.0

20.0–84.0

19.0–85.0

201 (54.2)

131 (53.0)

70 (56.5)

5 (1.3)

4 (1.6)

1 (0.8)

Intermediate

271 (73.0)

182 (73.7)

89 (71.8)

Unfavorable

37 (10.0)

26 (10.5)

11 (8.9)

Unknown

58 (15.6)

35 (14.2)

23 (18.5)

Anthracycline

311 (83.8)

205 (83.0)

106 (85.5)

FLT3 inhibitor

46 (12.4)

32 (13.0)

14 (11.3)

HSCT

74 (19.9)

48 (19.4)

26 (21.0)

Relapse

225 (60.6)

149 (60.3)

76 (61.3)

Primary refractory disease without HSCT

146 (39.4)

98 (39.7)

48 (38.7)

High-intensity chemotherapy

224 (60.4)

149 (60.3)

75 (60.5)

Low-intensity chemotherapy

147 (39.6)

98 (39.7)

49 (39.5)

ITD only

328 (88.4)

215 (87.0)

113 (91.1)

TKD only

31 (8.4)

21 (8.5)

10 (8.1)

7 (1.9)

7 (2.8)

0

Female sex — no. (%)
Cytogenetic risk status — no. (%)
Favorable

Previous therapy for AML — no. (%)

Response to first-line therapy before enrollment — no. (%)†

Preselected salvage chemotherapy per IRT —
no. (%)

FLT3 mutation subtype — no. (%)‡

ITD and TKD

*	The intention-to-treat population included all the patients who underwent randomization. Percentages may not total
100 because of rounding. AML denotes acute myeloid leukemia, HSCT hematopoietic stem-cell transplantation, ITD
internal tandem duplication, and TKD tyrosine kinase domain.
†	Response was based on findings from interactive response technology (IRT).
‡	Central laboratory confirmed the FLT3 mutation status. Five patients (1.3%) had unconfirmed FLT3 mutations; four
patients (1.6%) were assigned to the gilteritinib group and one (0.8%) to the chemotherapy group.

refractory AML, the median overall survival was
10.4 months in the gilteritinib group and 6.9
months in the chemotherapy group (hazard ratio
for death, 0.99; 95% CI, 0.63 to 1.55) (Table S3).
Although a higher percentage of patients underwent transplantation in the gilteritinib group
than in the chemotherapy group (25.5% [63 of
247 patients] vs. 15.3% [19 of 124 patients]), the
overall survival advantage for gilteritinib was
also maintained when survival data were censored at the time of transplantation (hazard ratio
for death, 0.58; 95% CI, 0.43 to 0.76) (Fig. S1).

n engl j med 381;18

Survival outcomes in patients who had been
preselected to receive high-intensity chemotherapy or low-intensity chemotherapy and in those
who had undergone transplantation previously
are presented in Table S4.
The median event-free survival was 2.8 months
in the gilteritinib group and 0.7 months in the
chemotherapy group (hazard ratio for treatment
failure or death, 0.79; 95% CI, 0.58 to 1.09) and
did not differ significantly between the treatment
groups (Fig. S2). Because the percentage of patients with composite complete remission in

nejm.org

October 31, 2019

1733

The New England Journal of Medicine
Downloaded from nejm.org at THOMAS JEFFERSON UNIVERSITY on November 20, 2019. For personal use only. No other uses without permission.
Copyright © 2019 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

of

m e dic i n e

A Overall Survival
1.0

Probability of Survival

0.9
0.8

Median
Overall Survival
(95% CI)
mo

0.7
0.6
0.5

Gilteritinib

0.4

Gilteritinib
Salvage Chemotherapy

0.3
0.2
0.1
0.0

Hazard ratio for death,
0.64 (95% CI, 0.49–0.83)
P<0.001

Salvage chemotherapy
0

3

6

9

12

9.3 (7.7–10.7)
5.6 (4.7–7.3)

15

18

21

24

27

30

33

36

14
7

11
5

4
3

1
1

0
0

0
0

Months
No. at Risk
Gilteritinib
Salvage chemotherapy

247
124

206
84

157
52

106
29

64
13

44
12

31
8

B Subgroup Analysis of Overall Survival
Salvage
Gilteritinib Chemotherapy

Subgroup

Hazard Ratio for Death (95% CI)

no. of events/total no. of patients
All patients
Age
<65 yr
≥65 yr
Sex
Male
Female
Race
White
Black
Asian
Other or unknown
ECOG performance-status score
0 or 1
≥2
Geographic region
North America
Europe
Asia
FLT3 mutation type
FLT3 ITD alone
FLT3 TKD alone
FLT3 ITD and FLT3 TKD
Other
Previous use of FLT3 inhibitor
Yes
No
Cytogenetic risk status
Favorable
Intermediate
Unfavorable
Unknown
Response to first-line therapy per IRT
Relapse ≤6 mo after allogeneic HSCT
Relapse >6 mo after allogeneic HSCT
Primary refractory disease without HSCT
Relapse ≤6 mo after composite complete remission and no HSCT
Relapse >6 mo after composite complete remission and no HSCT
Preselected chemotherapy per IRT
High intensity
Low intensity

171/247

90/124

0.64 (0.49–0.83)

91/141
80/106

52/75
38/49

0.61 (0.43–0.86)
0.64 (0.44–0.95)

86/116
85/131

40/54
50/70

0.72 (0.49–1.05)
0.57 (0.40–0.82)

102/145
13/14
42/69
14/19

56/75
6/7
20/33
8/9

0.72 (0.52–1.00)
0.54 (0.18–1.63)
0.34 (0.20–0.60)
0.87 (0.36–2.12)

138/206
33/41

78/105
12/19

0.60 (0.45–0.79)
0.87 (0.45–1.69)

88/114
43/68
40/65

42/52
32/43
16/29

0.72 (0.50–1.05)
0.67 (0.43–1.07)
0.38 (0.21–0.69)

145/215
16/21
6/7
4/4

81/113
8/10
0
1/1

0.62 (0.47–0.82)
0.69 (0.29–1.64)
NE (NE–NE)
0.70 (0.06–7.92)

26/32
145/215

11/14
79/110

0.70 (0.35–1.44)
0.62 (0.47–0.82)

3/4
119/182
22/26
27/35

1/1
63/89
7/11
19/23

0.70 (0.06–7.92)
0.60 (0.44–0.82)
1.63 (0.69–3.85)
0.46 (0.25–0.84)

24/31
10/17
70/98
47/67
20/34

16/17
4/8
28/48
28/34
14/17

0.38 (0.20–0.75)
0.86 (0.26–2.80)
0.99 (0.63–1.55)
0.49 (0.30–0.80)
0.49 (0.25–0.98)

96/149
75/98

52/75
38/49

0.66 (0.47–0.93)
0.56 (0.38–0.84)
0.1
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Figure 2 (facing page). Overall Survival among Patients
with FLT3-Mutated Relapsed or Refractory AML Treated
with Gilteritinib or Salvage Chemotherapy (Intention-toTreat Population).
Panel A shows the Kaplan–Meier estimate of overall
survival, and Panel B the hazard ratio for death in subgroup analyses. Two-sided P values were determined
by the log-rank test; the Kaplan–Meier method in combination with the Greenwood formula was used to determine overall survival and corresponding 95% con
fidence intervals (CIs). Tick marks indicate censored
data. The forest plot is shown on a log 2 scale. Arrows
indicate confidence intervals that extend beyond the
scale of the graph. Race was reported by the patients
and was categorized by the investigators on the basis
of the listed categories. Eastern Cooperative Oncology
Group (ECOG) performance-status scores range from
0 to 5, with higher scores indicating worse functional
status and a score of 5 indicating death. Patients from
Israel or Turkey were included with those from Europe.
FLT3 mutation subtypes were internal tandem duplication (ITD) and tyrosine kinase domain (TKD) and were
assessed centrally; other subtype included unknown,
missing, or negative. HSCT denotes hematopoietic stemcell transplantation, IRT interactive response technology,
and NE not evaluated.

the low-intensity chemotherapy subgroup was
4% (2 of 49 patients), the event-free survival in
the chemotherapy group was largely derived
from the high-intensity chemotherapy subgroup.
Because relapse events were defined on the basis
of central review of bone marrow biopsy specimens, nearly all the patients who had a response
to high-intensity chemotherapy and entered longterm follow-up had their data censored for eventfree survival at 1 to 2 months after randomi
zation, which limited the usefulness of the
protocol-defined analysis of event-free survival.
We performed a prespecified sensitivity analysis
of event-free survival that included investigatorreported events during the long-term follow-up
period (including the initiation of new antileukemic therapy), which showed event-free survival
of 2.3 months in the gilteritinib group and 0.7
months in the chemotherapy group (hazard ratio,
0.50; 95% CI, 0.39 to 0.64) (Fig. S3).
The percentage of patients who had complete
remission with full or partial hematologic recovery was 34.0% in the gilteritinib group and
15.3% in the chemotherapy group (risk difference,
18.6 percentage points; 95% CI, 9.8 to 27.4); the
percentages of patients with complete remission
were 21.1% and 10.5%, respectively (risk differn engl j med 381;18

ence, 10.6 percentage points; 95% CI, 2.8 to 18.4)
(Table 2). The median duration of complete remission with full or partial hematologic recovery was 11.0 months in the gilteritinib group but
could not be evaluated in the chemotherapy
group because of censoring. The percentages of
patients who had remission after an increase
in the dose of gilteritinib (78 patients) or a decrease in the dose (58 patients) are shown in
Table S5. When we excluded remissions that occurred after transplantation during the trial, the
percentage of patients who had complete remission with full or partial hematologic recovery
was 26.3% in the gilteritinib group and 15.3% in
the chemotherapy group (risk difference, 10.9 percentage points; 95% CI, 2.4 to 19.5). Among patients with primary refractory AML, the percentage of patients who had complete remission with
full or partial hematologic recovery was 32% (31
of 98 patients) in the gilteritinib group and 21%
(10 of 48 patients) in the chemotherapy group
(Table S3). The percentages of patients with a
remission according to chemotherapy intensity
and receipt or nonreceipt of previous transplantation are presented in Table S4.
Among patients with FLT3 ITD mutations who
had been randomly assigned to the gilteritinib
group, 20.5% had a complete remission; among
those who had been randomly assigned to chemotherapy, 9.7% had a complete remission (Table
S6). Although the percentages of patients with
complete remission were similar across the treatment groups among patients with FLT3 TKD
mutations, gilteritinib therapy resulted in similar
percentages of complete remission among patients with FLT3 TKD mutations alone (19.0%)
and among those with FLT3 ITD mutations alone
(20.5%) (Table S6). Among patients treated with
gilteritinib, the median overall survival was
similar among those with FLT3 ITD mutations
alone (9.3 months) and those with FLT3 TKD
mutations alone (8.0 months). The most commonly co-mutated genes were NPM1 (46.6%) and
DNMT3A (31.0%). Longer survival was observed
with gilteritinib than with chemotherapy across
all cohorts of patients with co-mutations, particularly in the cohort of patients with double mutation (DNMT3A and NPM1). Baseline levels of AXL
expression did not influence survival with gilteritinib. (Details are provided in Figs. S4 and S5.)
Overall, 197 of 247 patients (79.8%) who had
been randomly assigned to the gilteritinib group
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Table 2. Antileukemic Responses (Intention-to-Treat Population).*
Gilteritinib
(N = 247)

Variable

Salvage Chemotherapy
(N = 124)

Hazard Ratio or
Risk Difference (95% CI)†

Median overall survival (95% CI) — mo

9.3 (7.7–10.7)

5.6 (4.7–7.3)

0.64 (0.49–0.83)

Median event-free survival (95% CI) — mo

2.8 (1.4–3.7)

0.7 (0.2–NE)

0.79 (0.58–1.09)

Complete remission

52 (21.1)

13 (10.5)

10.6 (2.8–18.4)

Complete remission or complete remission
with partial hematologic recovery

84 (34.0)

19 (15.3)

18.6 (9.8–27.4)

Complete remission with partial hematologic
recovery

32 (13.0)

6 (4.8)

ND

Complete remission with incomplete hematologic
recovery

63 (25.5)

14 (11.3)

ND

Complete remission with incomplete platelet
recovery

19 (7.7)

0

ND

Response — no. (%)

Partial remission

33 (13.4)

5 (4.0)

ND

No response

66 (26.7)

43 (34.7)

ND

Composite complete remission‡

134 (54.3)

27 (21.8)

32.5 (22.3–42.6)

Overall response

167 (67.6)

32 (25.8)

Median duration of remission (95% CI) — mo§

11.0 (4.6–NE)

NE (NE–NE)

NE

Time to composite complete remission — mo

2.3±1.9

1.3±0.5

NA

Median leukemia-free survival (95% CI) — mo

4.4 (3.6–5.2)

6.7 (2.1–8.5)

NE

*	Plus–minus values are means ±SD. Data shown are the best response at any time postbaseline. Data include 366 patients with central laboratory–confirmed FLT3 mutations and 5 patients with FLT3 mutations that were not confirmed by a central laboratory and were based on local
laboratory testing. Response could not be evaluated (NE) in 14 patients (5.7%) in the gilteritinib group and in 49 (39.5%) in the salvage
chemotherapy group. NA denotes not applicable, and ND not determined.
†	Hazard ratios are shown for survival analyses, and risk differences (shown in percentage points) are shown for between-group differences in
the percentages of patients. In the analysis of overall survival, the hazard ratio is for death. In the analysis of event-free survival, the hazard
ratio is for treatment failure (i.e., relapse or lack of remission) or death.
‡	Composite complete remission was defined as the combination of complete remission, complete remission with incomplete hematologic
recovery, and complete remission with incomplete platelet recovery.
§	Duration of remission was defined as the duration of complete remission with full or partial hematologic recovery.

were transfusion-dependent at randomization. A tions of the liver aminotransferase levels. (Details
total of 68 of these 197 patients (34.5%) became are provided in Tables S7 and S8.)
transfusion-independent.
Common adverse events of grade 3 or higher
in the gilteritinib group were febrile neutropenia
Safety
(45.9%), anemia (40.7%), and thrombocytopenia
The median duration of exposure to gilteritinib (22.8%) (Table 3 and Table S9); these were also
and chemotherapy was 18 weeks (interquartile the most common adverse events of grade 3 or
range, 9 to 34) and 4 weeks (interquartile range, higher that were considered by the investigators
4 to 4), respectively; treatment exposure was to be related to gilteritinib therapy (Table S10).
121.7 patient-years and 11.9 patient-years, respec- The incidence of exposure-adjusted adverse events
tively. The incidence of all exposure-adjusted ad- of grade 3 or higher was 19.34 events per paverse events, including those that were consid- tient-year in the gilteritinib group and 42.44
ered by the investigator to be drug-related, was events per patient-year in the chemotherapy
higher in the chemotherapy group than in the group. Adverse events of grade 3 or higher that
gilteritinib group. Similar results were observed occurred during the first 30 days of treatment
regarding adverse events that occurred during are presented in Table S8.
the first 30 days of treatment, except for elevaThe incidence of exposure-adjusted serious
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Table 3. Incidence of Adverse Events during Treatment That Occurred in at Least 20% of the Patients in Either Treatment Group (Safety
Analysis Population).*
Event

Gilteritinib (N = 246)
Adverse Event
of Any Grade

Salvage Chemotherapy (N = 109)

Grade ≥3
Serious
Adverse Event Adverse Event

Adverse Event
of Any Grade

Grade ≥3
Adverse Event

Serious
Adverse Event

number of patients (percent)
Febrile neutropenia

115 (46.7)

113 (45.9)

76 (30.9)

40 (36.7)

40 (36.7)

9 (8.3)

Anemia

116 (47.2)

100 (40.7)

8 (3.3)

38 (34.9)

33 (30.3)

0

Pyrexia

105 (42.7)

8 (3.3)

32 (13.0)

32 (29.4)

4 (3.7)

1 (0.9)

Alanine aminotransferase
increased

103 (41.9)

34 (13.8)

13 (5.3)

10 (9.2)

5 (4.6)

0

Diarrhea

81 (32.9)

9 (3.7)

10 (4.1)

32 (29.4)

3 (2.8)

0

Aspartate aminotransferase
increased

99 (40.2)

36 (14.6)

10 (4.1)

13 (11.9)

2 (1.8)

0

Hypokalemia

71 (28.9)

32 (13.0)

0

34 (31.2)

12 (11.0)

1 (0.9)

Constipation

76 (30.9)

2 (0.8)

0

16 (14.7)

0

0

Fatigue

70 (28.5)

6 (2.4)

4 (1.6)

14 (12.8)

2 (1.8)

1 (0.9)

Platelet count decreased

56 (22.8)

54 (22.0)

5 (2.0)

28 (25.7)

27 (24.8)

0

Cough

72 (29.3)

1 (0.4)

2 (0.8)

11 (10.1)

0

0

Thrombocytopenia

63 (25.6)

56 (22.8)

4 (1.6)

18 (16.5)

18 (16.5)

1 (0.9)

Headache

64 (26.0)

3 (1.2)

5 (2.0)

16 (14.7)

0

0

Peripheral edema

59 (24.0)

1 (0.4)

0

13 (11.9)

0

0

Vomiting

53 (21.5)

1 (0.4)

1 (0.4)

15 (13.8)

0

0

Dyspnea

58 (23.6)

10 (4.1)

10 (4.1)

7 (6.4)

3 (2.8)

2 (1.8)

Blood alkaline phosphatase
increased

56 (22.8)

7 (2.8)

1 (0.4)

2 (1.8)

0

0

*	The events shown are limited to adverse events that had a difference in incidence of more than 2 percentage points between the treatment
groups. The safety population comprised all the patients who had received at least one dose of trial treatment.

adverse events, including those that were considered by the investigator to be drug-related, was
7.11 events per patient-year in the gilteritinib
group and 9.24 events per patient-year in the
chemotherapy group. The most common serious
adverse events that were considered to be related
to gilteritinib therapy were febrile neutropenia
(23 patients [9.3%]), increase in the alanine aminotransferase level (11 patients [4.5%]), and increase
in the aspartate aminotransferase level (10 patients [4.1%]). Drug-related adverse events leading to the discontinuation of gilteritinib occurred
in 27 patients (11.0%); the most common events
were elevated aspartate aminotransferase level
(4 patients [1.6%]), elevated alanine aminotransferase level (3 [1.2%]), and pneumonia (3 [1.2%])
(Table S11). Prolonged corrected QT intervals

n engl j med 381;18

calculated with Fridericia’s formula (QTcF intervals) that were considered to be possibly related
to gilteritinib therapy occurred in 12 patients
(4.9%), but only 1 patient (0.4%) had a maximum
postbaseline increase in the mean QTcF interval
of more than 500 msec. Dose reductions occurred
in 6 patients who had a mean change from the
baseline QTcF interval of more than 60 msec.
There were 251 deaths in the safety population of 355 patients, including 170 deaths among
246 patients (69.1%) in the gilteritinib group and
81 deaths among 109 patients (74.3%) in the
chemotherapy group. In the intention-to-treat
population, mortality at 30 days and at 60 days
was 2.0% and 7.7%, respectively, in the gilteritinib group and 10.2% and 19.0%, respectively,
in the chemotherapy group. Common fatal ad-
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verse events in both groups were disease progression (30 patients [12.2%] in the gilteritinib
group and 5 patients [4.6%] in the chemotherapy group) and infection (28 patients [11.4%] and
7 patients [6.4%], respectively). The most common fatal adverse events that were considered by
the investigator to be drug-related in the gilteritinib group were pneumonia (3 patients [1.2%]),
large intestine perforation (2 [0.8%]), and septic
shock (2 [0.8%]); those in the chemotherapy
group were sepsis (2 patients [1.8%]) and respiratory failure (2 [1.8%]) (Table S12).

Discussion
Treatment options for patients with relapsed or
refractory FLT3-mutated AML are largely limited
to various salvage chemotherapy regimens, and
there is no consensus regarding an approach.
We found that in this population of patients,
gilteritinib resulted in superior overall survival
and percentages of remission as compared with
salvage chemotherapy.
The efficacy of midostaurin plus chemotherapy for newly diagnosed FLT3-mutated AML
showed the usefulness of targeting FLT319; however, midostaurin has negligible activity in patients with relapsed or refractory AML.14 Results
from a similarly designed trial (QuANTUM-R)
that compared quizartinib with salvage chemotherapy in patients with FLT3 ITD–positive relapsed or refractory AML provide further evidence that targeting FLT3 prolongs survival as
compared with salvage chemotherapy.21 The present trial enrolled patients with FLT3 ITD or FLT3
TKD mutations. Although FLT3 TKD mutations
are uncommon at disease recurrence, they consistently and rapidly emerge during FLT3 inhibitor therapy to confer secondary resistance.22,34
Gilteritinib had clinical activity in all studied
FLT3 mutation types. Not only were the percentages of patients with complete remission similar
in the FLT3 TKD and ITD cohorts, but the median overall survival in these two cohorts was
also similar. Small sample sizes and challenges
of multiple comparisons limit the statistical
power and conclusiveness of subgroup analyses,
including the subgroup analyses of FLT3 TKD–
positive relapsed or refractory AML (38 patients)
and primary refractory AML (146 patients). Overall, gilteritinib showed a consistent survival bene
fit across many subgroups.
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Our trial showed a survival advantage for
FLT3-targeted therapy in patients with relapsed
or refractory AML after data were censored for
transplantation. Although gilteritinib therapy
resulted in 63 patients being able to undergo
transplantation, the contribution of the transplantation to the survival benefit from gilteritinib
is difficult to assess. Although long-term survival
after transplantation appeared to be associated
with resumption of gilteritinib therapy, many factors may have contributed to this observation; we
therefore caution against overinterpretation of
this nonrandomized analysis. Regardless of transplantation, few patients with long-term survival
were observed in either treatment group. Trials of
gilteritinib as part of first-line induction or consolidation therapy and as postconsolidation or posttransplantation maintenance therapy (ClinicalTrials
.gov numbers, NCT02927262, NCT02997202, and
NCT02752035) are under way to assess the role
of timing of anti-FLT3 intervention in improving
treatment outcomes.
A limitation is that our trial design provided
an imperfect estimate of response duration in
the chemotherapy group for the comparison of
event-free survival. In addition, enrollment occurred before widespread use of midostaurin in
first-line chemotherapy, which could plausibly
generate resistance to FLT3-targeted therapy and
subsequently alter gilteritinib activity. Evidence
suggests that mutational activation of RAS–RAF
and related mitogen-associated protein kinase
signaling frequently underlies secondary clinical
resistance to gilteritinib,35 but the causes of primary resistance require further investigation.
In conclusion, gilteritinib therapy led to higher
percentages of patients with response and longer
survival than salvage chemotherapy among patients with relapsed or refractory FLT3-mutated
AML. The main toxic effect was myelosuppression. A small signal regarding hepatic toxic effects bears attention in future studies.
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Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France (C.R.); Sendai Medical Center, National Hospital Organization, Sendai (H.Y.), and University of Fukui, Fukui (N.
Hosono) — both in Japan; Seoul National University (S.-S.Y.) and Asan Medical Center, University of Ulsan College of Medicine (J.-H.L.)
— both in Seoul, South Korea; Wake Forest Baptist Medical Center, Winston-Salem, NC (T.P.); and Massachusetts General Hospital,
Harvard Medical School, Boston (A.T.F.).
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